Push­ing the pos­i­tive in p=0.05, Red­Hill says it’s ready for a piv­otal IBD test

Red­Hill Bio­Phar­ma $RDHL pushed hard to tout the da­ta from a Phase II study for ir­ri­ta­ble bow­el dis­ease, but the stock start­ed to slide this morn­ing as the on­line gam­bling crowd start­ed to tease out the mean­ing of the p=0.05 bot­tom line that came with the da­ta.

That’s right on the bor­der of vic­to­ry and de­feat in a clin­i­cal study, and not all ob­servers were ready to cheer the da­ta along­side Red­hill ex­ecs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.